May 27, 2022
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022
May 04, 2022
Immutep Presents New and Significant Data from the AIPAC Study
Apr 28, 2022
Immutep Quarterly Activities Report
Apr 27, 2022
Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting
Mar 29, 2022
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
